RecruitingPhase 4NCT05292339

Ketorolac in Upper Extremity Tendinopathy and Arthropathy

Single Blind RCT to Evaluate the Effect of Ketorolac in Upper Extremity Tendinopathy and Arthropathy


Sponsor

Emory University

Enrollment

160 participants

Start Date

Jan 31, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Osteoarthritis (OA) and inflammatory conditions of the tendons and joints of the shoulder, elbow, hand, and wrist are common yet disabling diseases. Standard management utilizes conservative measures to minimize pain and improve function. Conservative pharmacological management commonly includes corticosteroid and ketorolac injections which have been well investigated as a modality of pain control and improved function in large joint OA. However, fewer studies yielding mixed results on the duration of symptomatic relief exist for arthropathy and tendinopathy of these joints. The goal of this study is to evaluate the efficacy of ketorolac and triamcinolone injections for common shoulder, elbow, wrist, and hand tendinopathy or arthropathy. Participants will be blinded to the treatment received. The duration of an individual participant's participation in this study is 24 weeks. During this time period, patients will be asked to return to the clinic for an in-person follow-up 6 weeks after the injection with either ketorolac or triamcinolone) in order to assess participants' outcomes. All work related to this project will take place at the Emory Sports Medicine Complex, Emory Executive Park, Emory Musculoskeletal Institute, the Emory University Orthopaedic and Spine Hospital, and the Emory Saint Joseph's Hospital. This study will add to existing knowledge by providing further insight into how wrist arthropathy should be most optimally and conservatively managed.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study compares two types of injections — ketorolac (an anti-inflammatory) versus triamcinolone (a steroid) — for treating pain and inflammation in the tendons and joints of the hand, wrist, elbow, and shoulder. Conditions include trigger finger, De Quervain's tenosynovitis, and various types of arthritis in the hand. You may be eligible if: - You are 18 years of age or older - You have a symptomatic tendon or joint condition of the hand, wrist, elbow, or shoulder - You have not had prior surgery for this condition You may NOT be eligible if: - You are under 18 years old - You have received triamcinolone or ketorolac injections in the past 6 months - You have previously had surgery for your hand condition - You have an allergy or contraindication to either medication - You have an active infection at the treatment site Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTriamcinolone injection to the shoulder, elbow, wrist, or hand

Triamcinolone is a corticosteroid that decreases the inflammatory process by inhibiting the release of arachidonic acid from phospholipids.

DRUGKetorolac injection to the shoulder, elbow, wrist, or hand

Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that reduces inflammation by inhibiting Cyclo-oxygenase (COX)-2 dependent prostaglandin release via the cyclooxygenase pathway.


Locations(4)

Emory Saint Joseph's Hospital

Atlanta, Georgia, United States

Emory University Orthopaedic and Spine Center

Atlanta, Georgia, United States

12 Executive Park Drive

Atlanta, Georgia, United States

Emory University Orthopaedic and Spine Hospital

Atlanta, Georgia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05292339


Related Trials